Alnylam Pharmaceuticals To Present New Clinical And Real-World Data Across Its Transthyretin-Mediated Amyloidosis And Hypertension Programs At ESC Congress 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced that it will present new clinical and real-world data across its transthyretin-mediated amyloidosis (ATTR) and
Alnylam is showing new research results about medicines it's working on at a big medical conference next year. When a company shares real patient data like this, it's a chance to see if their treatments are actually helping people—a sign of how strong their pipeline might be.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.